

HR 2011

Protecting Access to Biosimilars Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 1, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 2, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/2011>

Sponsor

Name: Rep. DeGette, Diana [D-CO-1]

Party: Democratic • **State:** CO • **Chamber:** House

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Apr 1, 2019
Rep. Reed, Tom [R-NY-23]	R · NY		Apr 1, 2019
Rep. Schrier, Kim [D-WA-8]	D · WA		Apr 1, 2019
Rep. Grothman, Glenn [R-WI-6]	R · WI		May 22, 2019
Rep. Crenshaw, Dan [R-TX-2]	R · TX		Jun 27, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 2, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 1895	Related bill	Jul 8, 2019: Placed on Senate Legislative Calendar under General Orders. Calendar No. 133.
116 S 1140	Related bill	Apr 11, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Protecting Access to Biosimilars Act of 2019

This bill excludes biological products that were initially licensed under the Federal Food, Drug, and Cosmetic Act (FD&C Act) (e.g., insulin) from the exclusivity protections that delay the licensure of biosimilar products under the Public Health Service Act (PHS Act). (The Biologics Price Competition and Innovation Act of 2009 generally requires that biological products approved under the FD&C Act are treated as though they were approved under the PHS Act through March 23, 2020.)

Actions Timeline

- **Apr 2, 2019:** Referred to the Subcommittee on Health.
- **Apr 1, 2019:** Introduced in House
- **Apr 1, 2019:** Referred to the House Committee on Energy and Commerce.